Authors: Sanchez, V Gimenez, S Haensler, J Geoffroy, C Rokbi, B Seguin, D Lissolo, L Harris, B Rizvi, F Kleanthous, H Monath, T Cadoz, M Guy, B

Citation: V. Sanchez et al., Formulations of single or multiple H-pylori antigens with DC Chol adjuvantinduce protection by the systemic route in mice - Optimal prophylactic combinations are different from therapeutic ones, FEMS IM MED, 30(2), 2001, pp. 157-165

Authors: Berencsi, K Gyulai, Z Gonczol, E Pincus, S Cox, WI Michelson, S Kari, L Meric, C Cadoz, M Zahradnik, J Starr, S Plotkin, S

Citation: K. Berencsi et al., A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects, J INFEC DIS, 183(8), 2001, pp. 1171-1179

Authors: Rokbi, B Seguin, D Guy, B Mazarin, V Vidor, E Mion, F Cadoz, M Quentin-Millet, MJ

Citation: B. Rokbi et al., Assessment of Helicobacter pylori gene expression within mouse and human gastric mucosae by real-time reverse transcriptase PCR, INFEC IMMUN, 69(8), 2001, pp. 4759-4766

Authors: Cadoz, M Meric, C

Citation: M. Cadoz et C. Meric, Cytomegalovirus vaccines - Future outlook, ARCH PED, 6, 1999, pp. 655S-658S

Authors: Adler, SP Plotkin, SA Gonczol, E Cadoz, M Meric, C Ben Wang, JA Dellamonica, P Best, AM Zahradnik, J Pincus, S Berencsi, K Cox, WI Gyulai, Z

Citation: Sp. Adler et al., A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne), J INFEC DIS, 180(3), 1999, pp. 843-846